Safety and efficacy of RT234 vardenafil inhalation powder on exercise parameters in pulmonary arterial hypertension: phase II, dose-escalation study design

Respiratory Research

Study Protocol

Mandar A. Aras¹  Veronica Franco²  Raymond L. Benza²  Carol Satler³  Leslie Spikes⁴  Daniel Grinnan⁵ 

[1] Division of Cardiology, University of California San Francisco, San Francisco, CA, USA;Division of Cardiovascular Medicine, The Ohio State University Wexner Medical Center, 410 W 10th Ave, 43210, Columbus, OH, USA;Respira Therapeutics, Inc., Boston, MA, USA;University of Kansas Medical Center, Kansas City, KS, USA;Virginia Commonwealth University School of Medicine, Richmond, VA, USA;

关键词: Cardiac output;    Clinical trial protocol;    Exercise test;    Pulmonary arterial hypertension;    Safety;    Treatment efficacy;    Vardenafil;    Vascular resistance;   

DOI  :  10.1186/s12931-022-02262-9

 received in 2022-08-19, accepted in 2022-11-27,  发布年份 2022

来源: Springer

【 摘 要 】

BackgroundPulmonary arterial hypertension (PAH) is a progressive disease characterized by high mean pulmonary arterial pressure (≥ 20 mmHg) and remodeling of the vascular arteries. Approved therapies improve symptoms and delay clinical worsening in the long term, but they do not relieve acute exertional symptoms. RT234, a drug/device combination (Respira Therapeutics, Palo Alto, CA, USA) that delivers the phosphodiesterase 5 inhibitor vardenafil to the lungs via inhalation, has been shown to reduce pulmonary vascular resistance in patients with PAH. This study aims to evaluate whether RT234 can increase oxygen capacity during cardiopulmonary exercise testing (CPET) in patients with PAH.MethodsThis prospective, multi-center, open-label, two-cohort, dose-escalation, phase IIb trial in patients with PAH will evaluate the safety and efficacy of RT234 in improving exercise parameters. The trial began in September 2020 and is expected to be completed by early 2024. Patients eligible for enrollment will have a right heart catheterization–confirmed diagnosis of PAH, a 6-minute walking distance of ≥ 150 m, a minute ventilation/carbon dioxide production slope of ≥ 36, and will be on up to three stable oral and/or inhaled (not parenteral) PAH-specific background therapies. The estimated sample size is 86 patients, who will be divided into two dose cohorts. Cohort 1 will receive 0.5 mg RT234, and cohort 2 will receive 1.0 mg RT234. Each cohort will contain two subgroups based on the number of PAH background medications (up to two vs three). The trial will assess patients’ changes from baseline in peak oxygen consumption (VO2) during CPET 30 minutes after a single dose of 0.5 mg or 1.0 mg RT234, the change in the 6-minute walking distance, and the pharmacokinetics and safety profile of single doses of RT234.ConclusionThis is the first trial involving an as-needed medication for PAH. The trial will provide insights into the safety and efficacy of as-needed RT234 in treating the acute symptoms of PAH during exercise and will inform the design of further trials.Trial registration number: ClinicalTrials.gov identifier NCT04266197.

【 授权许可】

CC BY   
© The Author(s) 2022

【 图 表 】

12982_2022_119_Article_IEq137.gif

12982_2022_119_Article_IEq133.gif

12888_2022_4365_Article_IEq35.gif